Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 5/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.38 |
| ▸ | RELA | Q04206 | 2/20 | 0.38 |
| ▸ | CFD | P00746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15541860 | 0.83 | MAOB (0.45) | EPHX2KDM1AMAOBNFKB1NFKB2 | |
| SCHEMBL15541573 | 0.83 | MAOB (0.45) | EPHX2KDM1AMAOBNFKB1NFKB2 | |
| SCHEMBL15541816 | 0.83 | MAOB (0.45) | EPHX2KDM1AMAOBNFKB1NFKB2 | |
| SCHEMBL2840520 | 0.75 | DRD2 (0.45) | EPHX2KDM1AMAOBNFKB1NFKB2 | |
| SCHEMBL20264346 | 0.72 | NFKB1 (0.44) | EPHX2KDM1ANFKB1NFKB2RELA | |
| SCHEMBL951707 | 0.72 | NFKB1 (0.44) | EPHX2KDM1ANFKB1NFKB2RELA | |
| SCHEMBL25069745 | 0.71 | KDM1A (0.54) | EPHX2KDM1AMAOB | |
| SCHEMBL5187892 | 0.71 | KMT2A (0.44) | HDAC4EPHX2KDM1AMAOBNFKB1 | |
| SCHEMBL25069709 | 0.71 | KDM1A (0.54) | EPHX2KDM1AMAOB | |
| SCHEMBL30012009 | 0.71 | KDM1A (0.60) | EPHX2KDM1AMAOBNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2867226-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2018-11-14 | — | — | EP | disclosed |
| US-9815819-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-9815819-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2017-11-14 | — | — | US | disclosed |
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2867226-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | Novartis AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014002051-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
| WO-2014002051-A2 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2014-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141455-A1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | C5, C3AR1, C9 | HDAC4 2994/4885EPHX2 783/4885KDM1A 4705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.